Scott C Howard
Overview
Explore the profile of Scott C Howard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
190
Citations
5394
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yao L, Eikelboom J, Macnab A, Yu Z, Cao Y, Wei W, et al.
Adv Biol (Weinh)
. 2025 Feb;
:e2400481.
PMID: 39950362
The prevailing focus of lifespan health research has predominantly centered on "healthy aging". This oversight may hinder the understanding of health across the lifespan, as disorders in earlier stages can...
2.
Tentoni N, Combs R, Hwang M, Ward S, McCracken A, Lowe J, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682236
Objectives: We aimed to determine whether the occurrence of early-onset toxicities due to 5-fluorouracil (5-FU) in treatment-naive patients undergoing their first cycle of FOLFOX/FOLFIRINOX was associated with decreased overall survival,...
3.
Gupta V, Satlin M, Yu K, Martei Y, Sung L, Westblade L, et al.
Cancer Med
. 2024 Dec;
13(24):e70495.
PMID: 39673173
Background: Infections are a leading cause of death in patients with cancer, but the proportion and rate of antimicrobial resistance (AMR) in hospitalized patients with cancer are not well understood....
4.
Tentoni N, Hwang M, Villanueva G, Combs R, Lowe J, Ramsey L, et al.
Cancer Med
. 2024 Sep;
13(17):e70176.
PMID: 39254047
Introduction: High-dose methotrexate (HDMTX) use can be limited by the development of acute kidney injury (AKI). Early AKI detection is paramount to prevent further renal injury and irreversible toxicities. This...
5.
Howard S, Avagyan A, Workeneh B, Pui C
Nat Rev Dis Primers
. 2024 Sep;
10(1):65.
PMID: 39251620
No abstract available.
6.
Howard S, Avagyan A, Workeneh B, Pui C
Nat Rev Dis Primers
. 2024 Aug;
10(1):58.
PMID: 39174582
Tumour lysis syndrome (TLS) represents a critical oncological emergency characterized by extensive tumour cell breakdown, leading to the swift release of intracellular contents into the systemic circulation, outpacing homeostatic mechanisms....
7.
Fischer J, Lertkovit O, Howard S, Assanasen C, Bleyer A
J Pediatr Hematol Oncol
. 2023 Nov;
46(1):e107-e110.
PMID: 37916829
Methotrexate is a major component of pediatric leukemia treatment. While toxicities are common after high-dose methotrexate, escalating dose methotrexate (Capizzi methotrexate) is typically well-tolerated. We report an adolescent Hispanic female...
8.
Villanueva G, Lowe J, Tentoni N, Taluja A, Villarroel M, Narvaez C, et al.
Pediatr Hematol Oncol
. 2023 Oct;
41(2):135-149.
PMID: 37865916
High-dose methotrexate (HDMTX) is used to treat a broad spectrum of cancers. Methotrexate (MTX) monitoring and adequate supportive care are critical for safe drug administration; however, MTX level timing is...
9.
Yao L, Chemaitelly H, Goldman E, Gudina E, Khalil A, Ahmed R, et al.
EClinicalMedicine
. 2023 Oct;
64:102222.
PMID: 37811488
In counteracting highly infectious and disruptive respiratory diseases such as COVID-19, vaccination remains the primary and safest way to prevent disease, reduce the severity of illness, and save lives. Unfortunately,...
10.
Buddington R, Wong T, Buddington K, Mikkelsen T, Cao X, Howard S
Front Nephrol
. 2023 Oct;
3:1193494.
PMID: 37790293
Introduction: Early identification of compromised renal clearance caused by high-dose methotrexate (HDMTX) is essential for initiating timely interventions that can reduce acute kidney injury and MTX-induced systemic toxicity. Methods: We...